QYQinwei Yu

Qinwei Yu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qinwei Yu has a total of 101 co-authors. Here are the top co-authors by number of shared publications:

  • Zhenzhou Jiang

    New Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China

    26 shared publications
  • Luyong Zhang

    New Drug Screening and Pharmacodynamics Evaluation Center, Jiangsu Center for Pharmacodynamics Research and Evaluation, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China

    13 shared publications
  • Qian Lu

    New Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China

    9 shared publications
  • Xue Fan

    New Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China

    8 shared publications
  • Luyong Zhang

    New Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China; Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou, 510006, China

    7 shared publications
  • Jie Wang

    New Drug Screening and Pharmacodynamics Evaluation Center, Jiangsu Center for Pharmacodynamics Research and Evaluation, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China

    6 shared publications

Latest Publications

  • Leflunomide‐inhibited STAT1 activity ameliorates intramuscular M1 macrophage infiltration and promotes muscle regeneration in Duchenne muscular dystrophy

    by Wanting Hu, Haowei Tong, Maolin Zhu, Huna Wang, Xiaofei Huang, Shusheng Fan, Guangyao Guo, Mohammed Ismail, Lei Zhao, Xihua Li, et al.

    Background and Purpose: Duchenne muscular dystrophy (DMD) is an X‐linked recessive disorder caused by dystrophin gene mutations. This study investigated the therapeutic effects of leflunomide, a STAT1 inhibitor on dystrophic muscles. Experimental Design: The characterization of M1 macrophage polarization and the level of STAT1/ p ‐STAT1 were measured in DMD patients. Lipopolysaccharide (LPS)/IFN‐γ and RO8191 were selected to stimulate STAT1 for evaluating the inhibitory effect of A771726 on M1 polarization and STAT1. Conditionally cocultured M1 RAW264.7 cells and differentiated C2C12 myoblasts were used to explore the differentiation of A771726 to myopathy in inflammatory environments. After 4‐week treatment with leflunomide, the protein levels of STAT1 and p ‐STAT1 were evaluated in mdx mice. CD86 and CD68 were selected for evaluating inflammation event. The proinflammatory cytokines were measured by RT‐PCR and ELISA. Muscle function and myofibre damage were examined by behavioural experiments and serum CK and LDH level, respectively. The muscle regeneration event was demonstrated by myosin heavy chain, myogenic differentiation (MyOD) protein levels and eMyHC immunofluorescence. Key Results: STAT1 was remarkably upregulated in mdx mice and DMD patients compared with control groups. A771726 restrained LPS/IFN‐γ‐induced M1 macrophage polarization via inhibiting p ‐STAT1 and STAT1. Specific activation of STAT1 by RO8191 promoted macrophage polarize towards M1 type, which was partially counteracted by A771726. Leflunomide‐inhibited inflammation infiltration mediated by M1 macrophage and exerted promising therapeutic effect on muscle repair in mdx mice. Conclusions and Implications: Leflunomide relieved M1 macrophage infiltration and improved muscle regeneration by downregulating STAT1 and p ‐STAT1. STAT1 may merge as a promising target for the therapy of DMD.

  • Fenofibrate anti-RARα/RXRα dimerization to attenuate all-trans retinoic acid-induced hyperlipidemia and hepatic steatosis in mice

    by Qian Lu, Ninglin Xia, Jicheng Wang, Yulin Yi, Xue Fan, Ming Jin, Xiaofei Huang, Wenwen Xin, Li Sun, Jinyu Hu, et al.

  • Obeticholic acid exacerbates liver injury through hepatocyte-mediated release of HMGB1 by inducing lysosomal membrane permeabilization in cholestasis

    by Jie Wang, Qianhui Tang, Zihang Yuan, Haoran Zhang, Yingying Miao, Qingyu Chen, Weishuang Shen, Qinwei Yu, Luyong Zhang, Zhenzhou Jiang


  • Fenofibrate promotes erucic acid metabolism by peroxisome enzyme EHHADH activation alleviating high-fat diet–induced steatotic liver disease

    by Ming Jin, Rongmi Zhang, Wenwen Xin, Li Sun, Xue Fan, Qian Lu, Luyong Zhang, Zhenzhou Jiang, Qinwei Yu


  • Immune-endothelial cell crosstalk in hepatic endothelial injury of liver fibrotic mice

    by Xue Fan, Qianhui Tang, Ninglin Xia, Jiwei Wang, Wen Zhao, Ming Jin, Qian Lu, Jinyu Hu, Rongmi Zhang, Luyong Zhang, et al.


  • Open Access

    Oestrogen Receptor Alpha in Myocyte Maintains Muscle Regeneration in Duchenne Muscular Dystrophy

    by Xiaofei Huang, Sijia Li, Huna Wang, Lei Zhao, Xihua Li, Shusheng Fan, Wanting Hu, Haowei Tong, Guangyao Guo, Dengqiu Xu, et al.

    Background: Oestrogen receptor alpha (ERα) plays an important role in maintaining mitochondrial function and regulating metabolism in skeletal muscle. However, its alterations and potential mechanisms in Duchenne muscular dystrophy (DMD) remain incompletely understood. In this study, we demonstrated the protective role of ERα in myocyte for skeletal muscle regeneration in mdx mice and explored the therapeutic effects of oestrogen receptor modulators on DMD. Methods: DMD patients' biopsies were obtained for histological analysis to explore the expression of ERα. The phenotype of muscle was analysed by histology and molecular biology. The therapeutical effect of different oestrogen receptor modulators was examined in mdx mice treated with fulvestrant (FVT, 20 mg/kg once a week) or oestradiol (E2, 1 mg/kg per day) for 4 weeks. The protective effect of ERα was performed on mdx mice after conditional knockout of ERα in skeletal muscle (ERα mKO mdx mice). Evidence of activation of ERα/oestrogen‐related receptor alpha (ERRα)/myogenic differentiation 1 (MyoD) signalling pathway was inspected in the primary myoblasts isolated from mice, and C2C12 cells received intervention with E2/FVT/ Esr1 ‐siRNA/ Esrra overexpression plasmid. Results: The ERα expression was increased in DMD patients' triceps ( p < 0.05) and mdx mice muscles ( p < 0.05). FVT reduced ERα levels in the mdx mice muscles ( p < 0.01) but had no significant effect on skeletal muscle regeneration on mdx mice. Compared with mdx mice, E2 reduced the levels of creatine kinase (CK) and lactic dehydrogenase (LDH) ( p < 0.001) in serum, enhanced skeletal muscle function, alleviated skeletal muscle atrophy and fibre loss and upregulated the expression of ERα in GAS ( p < 0.001) and TA ( p < 0.05). The myogenic factors such as myosin heavy chain (MyHC, p < 0.001), myogenin (MyoG, p < 0.05), MyoD ( p < 0.05) and ERRα ( p < 0.001) were increased in mdx mice GAS with E2. But E2 had no effect on ERα mKO mdx mice. The primary myoblasts and C2C12 were treated with E2 displayed an increased‐on myocyte fusion index ( p < 0.05), ERα MyoD and ERRα expressions ( p < 0.05). The myocytes' fusion index ( p < 0.05) and ERα, MyoD and ERRα expression ( p < 0.05) were decreased in si‐ Esr1 ‐transfected C2C12 cells and increased in OE‐ Esrra ‐transfected C2C12 cells. Conclusion: We demonstrated that ERα in myocyte exerted a protective effect on skeletal muscle regeneration in DMD patients and mdx mice through the ERα‐ERRα‐MyoD pathway, which has potential implications for DMD therapy strategies.


  • Open Access

    LncRNA Gm35585 transcriptionally activates the peroxidase EHHADH against diet-induced fatty liver

    by Ming Jin, Qian Lu, Ninglin Xia, Xue Fan, Ziling Zhang, Xiaofei Huang, Li Sun, Luyong Zhang, Zhenzhou Jiang, Qinwei Yu

    Metabolic-dysfunction-associated steatotic liver disease is one of the most common chronic liver diseases worldwide and has no approved treatment thus far. Here we report that the hepatic overexpression of Gm35585, a novel lncRNA downregulated in the livers of mice fed a high-fat diet, is functionally important in alleviating hepatic lipid accumulation pathologies. Gm35585 activates the peroxisome proliferator-activated receptor α (PPARα) signaling pathway and promotes the expression of downstream PPARα-target gene, enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase (EHHADH), which is one of the four enzymes of the peroxisomal β-oxidation pathway. Activation of EHHADH promotes the oxidation of long-chain fatty acids (LCFAs), and the increased levels of hepatic LCFAs contribute to metabolic-dysfunction-associated steatotic liver disease. Mechanistically, Gm35585 binds to retinoid X receptor α (RXRα) and then forms a PPARα/RXRα heterodimer with PPARα and guides the heterodimer to recognize the promoter of EHHADH, which is called peroxisome proliferator-activated receptor response element, causing transcriptional activation of EHHADH. Taken together, Gm35585 is a hepatic lipid metabolism regulator that activates EHHADH transcription, promoting peroxisomal β-oxidation of LCFAs and ultimately ameliorating diet-induced fatty liver.


  • Obeticholic acid aggravates liver fibrosis by activating hepatic farnesoid X receptor-induced apoptosis in cholestatic mice

    by Qian Lu, Jingyi Yu, Ninglin Xia, Ming Jin, Wen Zhao, Xue Fan, Rongmi Zhang, Jie Wang, Zhenzhou Jiang, Qinwei Yu


  • Open Access

    Silybin Meglumine Mitigates CCl4-Induced Liver Fibrosis and Bile Acid Metabolism Alterations

    by Xiaoxin Liu, Ninglin Xia, Qinwei Yu, Ming Jin, Zifan Wang, Xue Fan, Wen Zhao, Anqin Li, Zhenzhou Jiang, Luyong Zhang

    Background: Altered patterns of bile acids (BAs) are frequently present in liver fibrosis, and BAs function as signaling molecules to initiate inflammatory responses. Silybin meglumine (SLB-M) is widely used in treating various liver diseases including liver fibrosis. However, research on its effects on bile acid (BA) metabolism is limited. This study investigated the therapeutic effects of SLB-M on liver fibrosis and BA metabolism in a CCl4-induced murine model. Methods: A murine liver fibrosis model was induced by CCl4. Fibrosis was evaluated using HE, picrosirius red, and Masson’s trichrome staining. Liver function was assessed by serum and hepatic biochemical markers. Bile acid (BA) metabolism was analyzed using LC-MS/MS. Bioinformatics analyses, including PPI network, GO, and KEGG pathway analyses, were employed to explore molecular mechanisms. Gene expression alterations in liver tissue were examined via qRT-PCR. Results: SLB-M treatment resulted in significant histological improvements in liver tissue, reducing collagen deposition and restoring liver architecture. Biochemically, SLB-M not only normalized serum liver enzyme levels (ALT, AST, TBA, and GGT) but also mitigated disruptions in both systemic and hepatic BA metabolism by increased unconjugated BAs like cholic acid and chenodeoxycholic acid but decreased conjugated BAs including taurocholic acid and taurodeoxycholic acid, compared to that in CCl4-induced murine model. Notably, SLB-M efficiently improved the imbalance of BA homeostasis in liver caused by CCl4 via activating Farnesoid X receptor. Conclusions: These findings underscore SLB-M decreased inflammatory response, reconstructed BA homeostasis possibly by regulating key pathways, and gene expressions in BA metabolism.